Using nanotechnology to engineer sensors onto the surface of cells, researchers at Brigham and Women's Hospital (BWH) have developed a platform technology for monitoring single-cell interactions in real-time. This innovation addresses needs in both science and medicine by providing the ability to further understand complex cell biology, track transplanted cells, and develop effective therapeutics. These findings are published in the July 17 issue of Nature Nanotechnology.
"We can now monitor how individual cells talk to one another in real-time with unprecedented spatial and temporal resolution," says Jeffrey Karp, senior study author, and co-director of the Center for Regenerative Therapeutics (ReGen Rx) at BWH. "This allows us to understand signaling between cells and interactions with drugs in great detail that should have broad implications for basic science and drug discovery",.The cell-signaling sensors researchers currently use are limited to measuring the activity in the bulk environment that a group of cells are in. In this study, researchers used nanotechnology to anchor a sensor to the membrane of individual cells, allowing them to monitor soluble signals within the cellular nanoenvironment. Given that cells are directly labeled with sensors permits application to transplanted cells or tissues.
The researchers are also especially excited by preliminary data that demonstrates the potential to use this engineering approach to track and monitor the environment surrounding transplanted cells, in real time, which was never before possible. This would be useful for developing a deeper understanding of signaling events that define a site of inflammation for example or the stem cell niche, which may have implications for treatment of many diseases.
"This new study takes a significant step toward the goal to eavesdrop in real-time and at high spatial resolution on communications between cells in their native environment, with far-reaching implications for the development of new drugs and diagnostics" said Ulrich von Andrian, the Mallinckrodt Professor of Immunopathology at Harvard Medical School who was not involved in this study.
This work was funded by the National Institutes of Health and the American Heart Association.
Brigham and Women's Hospital (BWH) is a 793-bed nonprofit teaching affiliate of Harvard Medical School and a founding member of Partners HealthCare, an integrated health care delivery network. BWH is the home of the Carl J. and Ruth Shapiro Cardiovascular Center, the most advanced center of its kind. BWH is committed to excellence in patient care with expertise in virtually every specialty of medicine and surgery. The BWH medical preeminence dates back to 1832, and today that rich history in clinical care is coupled with its national leadership in quality improvement and patient safety initiatives and its dedication to educating and training the next generation of health care professionals. Through investigation and discovery conducted at its Biomedical Research Institute (BRI), BWH is an international leader in basic, clinical and translational research on human diseases, involving more than 900 physician-investigators and renowned biomedical scientists and faculty supported by more than $537 M in funding. BWH is also home to major landmark epidemiologic population studies, including the Nurses' and Physicians' Health Studies and the Women's Health Initiative. For more information about BWH, please visit www.brighamandwomens.org
Holly Brown-Ayers | EurekAlert!
The dense vessel network regulates formation of thrombocytes in the bone marrow
25.07.2017 | Rudolf-Virchow-Zentrum für Experimentelle Biomedizin der Universität Würzburg
Fungi that evolved to eat wood offer new biomass conversion tool
25.07.2017 | University of Massachusetts at Amherst
21.07.2017 | Event News
19.07.2017 | Event News
12.07.2017 | Event News
25.07.2017 | Physics and Astronomy
25.07.2017 | Earth Sciences
25.07.2017 | Life Sciences